|
JP2002518521A
(ja)
|
1998-06-20 |
2002-06-25 |
ワシントン・ユニバーシティ |
医用画像解析、診断および治療のための膜透過性ペプチド錯体
|
|
IL127773A0
(en)
|
1998-12-28 |
1999-10-28 |
Yeda Res & Dev |
Saccharide conjugates and pharmaceutical compositions comprising them
|
|
SE0201863D0
(en)
|
2002-06-18 |
2002-06-18 |
Cepep Ab |
Cell penetrating peptides
|
|
US9740817B1
(en)
|
2002-10-18 |
2017-08-22 |
Dennis Sunga Fernandez |
Apparatus for biological sensing and alerting of pharmaco-genomic mutation
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
AU2004235396B2
(en)
|
2003-04-29 |
2010-11-25 |
Sarepta Therapeutics, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
|
CA2543722C
(en)
|
2003-10-29 |
2011-01-04 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
|
ES2627917T3
(es)
|
2004-06-28 |
2017-08-01 |
The University Of Western Australia |
Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
IE20060565A1
(en)
|
2006-07-28 |
2008-02-06 |
Eurand Pharmaceuticals Ltd |
Drug delivery system based on regioselectively amidated hyaluronic acid
|
|
WO2008109105A2
(en)
|
2007-03-06 |
2008-09-12 |
Flagship Ventures |
Methods and compositions for improved therapeutic effects with sirna
|
|
US20080306001A1
(en)
|
2007-04-04 |
2008-12-11 |
Anzelika Liik |
Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
|
|
CA2691673A1
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
EP2249851B1
(en)
|
2008-02-13 |
2015-04-01 |
Kao Corporation |
Method for producing hippocastanaceae plant seed extract
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
WO2009147368A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
SI2607484T1
(sl)
|
2008-10-27 |
2016-11-30 |
Biomarin Technologies B.V. |
Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
HUE040445T2
(hu)
|
2009-11-12 |
2019-03-28 |
Univ Western Australia |
Antiszensz molekulák és eljárások betegségek kezelésére
|
|
NZ704191A
(en)
|
2010-06-14 |
2016-05-27 |
Hoffmann La Roche |
Cell-penetrating peptides and uses therof
|
|
EP2394665A1
(en)
*
|
2010-06-14 |
2011-12-14 |
F. Hoffmann-La Roche AG |
Cell-penetrating peptides and uses therof
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
JP6069212B2
(ja)
|
2010-12-02 |
2017-02-01 |
ビオノール イミュノ エーエスBionor Immuno As |
ペプチド骨格設計
|
|
WO2012090150A2
(en)
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
New cell-penetrating peptides and uses thereof
|
|
AU2011367230B2
(en)
|
2011-05-05 |
2017-08-10 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2013030569A2
(en)
*
|
2011-08-30 |
2013-03-07 |
Michael John Gait |
Peptides
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
BR112014027239A2
(pt)
|
2012-06-26 |
2017-07-18 |
Hoffmann La Roche |
peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
|
|
AU2013316679B2
(en)
|
2012-09-13 |
2017-12-14 |
Les Hopitaux Universitaires De Geneve |
Cell penetrating peptides
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
US10111962B2
(en)
|
2012-09-25 |
2018-10-30 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
GB201314411D0
(en)
*
|
2013-08-12 |
2013-09-25 |
Medical Res Council |
Peptide conjugates
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
US10358643B2
(en)
|
2014-01-30 |
2019-07-23 |
Hoffmann-La Roche, Inc. |
Poly oligomer compound with biocleavable conjugates
|
|
WO2015161255A1
(en)
|
2014-04-18 |
2015-10-22 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
|
|
RU2708237C2
(ru)
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
EP3034074A1
(en)
|
2014-12-18 |
2016-06-22 |
Universitat De València, Estudi General |
Compound for treatment of myotonic dystrophy type 1
|
|
US10017542B2
(en)
|
2015-03-23 |
2018-07-10 |
Riptide Bioscience, Inc. |
Antimicrobial peptides and methods of use thereof
|
|
JP6817288B2
(ja)
|
2015-08-10 |
2021-01-20 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
新規な連結体及び生体分子と薬物との特異的共役におけるその使用
|
|
US10858410B2
(en)
|
2015-08-12 |
2020-12-08 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス, インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
DK3463308T4
(da)
|
2016-06-01 |
2026-02-09 |
Servier Ip Uk Ltd |
Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
|
|
CN110392583B
(zh)
|
2016-09-15 |
2023-01-03 |
加利福尼亚大学董事会 |
改进的杂化的末端树枝状聚合物
|
|
WO2018150196A1
(en)
|
2017-02-17 |
2018-08-23 |
Oxford University Innovation Limited |
Cell penetrating peptides modified by glycosylation
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
AU2019394177A1
(en)
|
2018-12-07 |
2021-06-10 |
Oxford University Innovation Limited |
Linkers
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
EP3997228A4
(en)
|
2019-07-09 |
2024-05-15 |
The Governors of the University of Alberta |
SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
|
|
GB201911403D0
(en)
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
CA3211038A1
(en)
|
2021-02-12 |
2022-08-18 |
Oxford University Innovation Limited |
Cell-penetrating peptide conjugates and methods of their use
|
|
US20240189434A1
(en)
|
2021-03-12 |
2024-06-13 |
Pepgen Inc. |
Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
|
|
US20240200062A1
(en)
|
2021-03-12 |
2024-06-20 |
Pepgen Inc. |
Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
|